Cancer is the one modern day sickness whose cure has eluded the medical community for many decades now. The best trials that have been done are radiotherapy and chemotherapy and this only works when cancer has not reached certain advanced stages. Scientists such as Clay Siegall have been researching on treatments that can deal with cancer once and for all and have confidence that their clinical trials are heading somewhere. Clay co-founded a clinical trials company known as Seattle Genetics in 1998. In the past twenty years, the company has been developing cures and treatment options for different types of tumors.
About two years ago, Siegall got his big break when the FDA approved one of the drugs he had been developing. The drug has since been adopted for use in treating different types of lymphomas in 66 countries. Also, Seattle Genetics is trading their shares on NASDAQ under the name SGEN. They have reported more than half a million dollars in drug sales since they started selling.
Clay states that things were not always as easy as they seem now. He confides that there were times when they were so strapped for cash that they couldn’t even afford a salary for their employees. The hard work and resilience have significantly paid off because now the company is selling their drugs abroad, and their chief marketer in Canada is Takeda Pharmaceuticals.
Clay states that the main aim of the research they are carrying out and the drugs they are creating is to build better outcomes by giving the patient strong antibody conjugates and directing them to the specific tumor cells. He adds that besides the one drug that has been approved, there are 11 others which are in different trial stages. He hopes that they will manage to get the drugs approved as well. To speed up the process of testing the drugs, they have expanded their capacity and hired more researchers to help with the process. Clay hopes that they will have an easy time dealing with FDA this time around and that their drugs will be a game changer in cancer treatment.
Eric Lefkofsky is the founder of the world famous technology startup Groupon that went on to become a multi-billion dollar enterprise and is today worth at more than $2 Billion. It is an online platform that helps the customers to connect with the merchants offering attractive discounts and deals. Groupon has helped many businesses increase their turnover and reach out to their clients more efficiently. It helps companies with marketing their products and services at a much faster pace, and also helps with providing customers with promotional deals at a much more rapidly pace. It is a high-performance platform that is mutually beneficial for the customers as well as the companies.
Eric Lefkofsky has started many other companies, which includes Uptake Technologies, Lightbank Investments, Echo Global Logistics, and Tempus Inc. Tempus is a business that he started recently with the aim to integrate advanced technology in the field of cancer research. Eric Lefkofsky through life experiences came to the realization that the area of cancer research can develop and grow at a much faster pace if the data and information of various cases can be accumulated together.It is what Tempus does today. It gathers the clinical as well as patient outcome data from over 6,000 medical facilities and hospitals and makes it available to the physicians and research scholars so that the field of cancer research can progress smoothly by using the data active in their research. It helps the doctors to offer a highly personalized and focused treatment to the patients after understanding from the past cases, whether a particular treatment would be effective for them or not. Tempus also takes into account the genomic data, which helps in getting the accuracy needed in the cancer therapies.
Eric Lefkofsky is also the author of one of the most famous books named Accelerated Disruption. The book talks about how the new start-ups are making decades-old companies look like a newcomer overnight. Accelerated Disruption helps the companies to integrate the much-needed change to adapt to the modern business environment and use technology as a tool to innovate and advance in any given industry, and retaining the competitive advantage over the new start-ups.
Seattle Genetics, a company that conducts cancer research, has recently been the topic of many discussions due to their new development of cancer fighting agents. The company has been developing these new antibiotic treatments for the last several years and have recently been approved for funding that can take their research to a new level. Dr. Clay Siegall, the Chief Executive Officer and President of Seattle Genetics, has recently given an interview regarding the new changes at his company. He has stated that he is extremely excited about the changes that Seattle Genetics is making in the cancer research industry and hopes that this new advancement will be instrumental in the healing of millions of people who suffer from cancer.
The new development that Seattle Genetics has been working on for the last several years is comprised of a medication that actively fights cancer antibodies in a patients body. If a person’s body is infected with cancer, cancer antibodies begin to grow at a rapid pace in the body. These antibodies create cells that actually kill the healthy cells and grow at a swift rate so that white blood cells can not kill them. By developing this new antibody fighting drug, Seattle Genetics has effectively changed the cancer industry. Now, there is a drug available that can specifically target the cancer cells and not the healthy cells in a patients body.
With most cancer fighting drugs, like chemotherapy for instance, the medicine works by targeting the cancer cells and the healthy cells in a patient’s body. The problem with these drugs have been that they generally cause the patient’s body to attack itself while it is attacking the cancer cells. This is the reason that most cancer patients become so ill and begin to lose their hair and the functionality in their bodies. The medicine has been formulated in such a way that it cannot distinguish between healthy and cancerous cells. This new development by Dr. Clay Siegall and his team at Seattle Genetics is a true innovation in the cancer research industry and can dramatically improve the lives of cancer patients around the world.
Cancer is one of those diseases which affect not only the patient but also their loved ones. When diagnosed with cancer, most patients see it as a death sentence from the beginning. The truth is that there are cures for different types of cancer. There are various treatment methods available and there are certain researchers and scientists who are still doing research to come up with even better and more effective treatment options.
When you have cancer, the doctors will start you on a treatment plan. Most of the time, the treatment involves the use of chemotherapy to kill the cancer cells. The treatment usually affects both the cancerous cells as well as the healthy ones. However, there is a company which has noticed this and has come up with a method of ensuring that only the cells with cancer are killed. The cells which are unaffected by cancer can be left alone to thrive.
Seattle Genetics is a company known in the biotechnology industry as a manufacturer and maker of innovative treatment technologies and products. They have come up with an innovative solution to this problem. This is in the form of a treatment known as ADC which actually means Anti-body Drug Conjugate. The technology sees to it that only cancerous cells are killed in the body.
The CEO and founder of Seattle Genetics is a reputed individual known as Clay Siegall. He founded the company in 1998 and he led it to where it is now. He is helped by a board of directors and he chairs the board. Mr Siegall is a scientist as well as an entrepreneur. He has gained recognition for his work both as a research with a passion and specialty in therapies, drugs and innovative treatment methods. As an entrepreneur, Siegall has been awarded several awards, including the 2012 Northwest Pacific Ernst & Young Entrepreneur of the Year.
Thanks to the ADC technology, patients can get the best treatment options for cancer and even recover faster after their sessions of chemotherapy. The team is driven by certain values among them integrity and a passion for whatever they do.